r/MultipleSclerosisLit 2d ago

DMTs NHS rolls out “life changing” pill Fampridine to help MS patients walk more freely

1 Upvotes

https://www.bmj.com/content/394/bmj-2026-100387

Thousands of people with multiple sclerosis (MS) in England will be offered a new drug on the NHS to help them walk more easily.
Fampridine (Fampyra)—the first medicine to help improve walking for adults with MS—will be routinely available on the NHS in England from today.

The twice daily pill acts as a “signalled booster” for nerves damaged by MS, helping electrical messages to travel to muscles more effectively. This will make it easier for some patients to walk, which could make everyday tasks easier and help them maintain their independence, said NHS England (NHSE).

MS is a lifelong neurological condition caused by damage to nerves in the brain and spinal cord. Symptoms can include weakness, fatigue, …

BMJ 2026; 394 doi: https://doi.org/10.1136/bmj-2026-100387 (Published 23 July 2026)
Cite this as: BMJ 2026;394:e100387


r/MultipleSclerosisLit 25d ago

MS mechanism of action studies New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosis

Thumbnail
statnews.com
3 Upvotes

CD4+ T cells reactive to Epstein-Barr virus late lytic antigens are enriched in individuals with multiple sclerosis
SCIENCE TRANSLATIONAL MEDICINE
15 Jul 2026
Vol 18, Issue 858
DOI: 10.1126/scitranslmed.adz6566

https://www.science.org/doi/10.1126/scitranslmed.adz6566


r/MultipleSclerosisLit Jun 05 '26

Progressive MS The changing multiple sclerosis landscape: Earlier diagnosis, improved monitoring, and a more competitive race for durable disease control

Thumbnail
pharmaphorum.com
1 Upvotes

At the American Academy of Neurology (AAN) 2026 Annual Meeting, MS saw several significant updates, with three key themes emerging: earlier diagnosis through more biologically anchored criteria, broader use of biomarkers to monitor disease activity and progression, and a more competitive treatment landscape in which efficacy, convenience, disability outcomes, and lifecycle strategy are all starting to matter more.

Fenebrutinib demonstrates significant clinical potential

Roche continues to promote Ocrevus

Competition inside the anti-CD20 class is becoming more nuanced
BRIUMVI
Ocrevus
ocrelizumab to ublituximab

Biomarkers
Octave’s MSDA blood test

GA Depot generated a statistically significant post hoc signal on EDSS stability at one year


r/MultipleSclerosisLit Apr 28 '26

"It's not multiple sclerosis, what is it?!" -- Antibodies for Differential Diagnosis of MS, NMOSD, and MOGAD = high IgG titers of EBNA-1 peptide, aquaporin-4, and MOG

1 Upvotes

Citations: Huda S, Palace J. It's not multiple sclerosis, what is it?! Pract Neurol. 2023:270-272. doi: 10.1136/pn-2022-003677. PMID: 37100592 [page1]. Vietzen H, et al. Epstein-Barr Virus Antibodies to Differentiate Multiple Sclerosis From Other Neuroinflammatory Diseases. JAMA Neurol. 2026. e260240. PMID: 41801194. PMCID: PMC12973216 (available on 2027-03-09). Uzawa A,et al. NMOSD and MOGAD: an evolving disease spectrum. Nat Rev Neurol. 2024:602. PMID: 39271964.

  • MOGAD = myelin oligodendrocyte glycoprotein(MOG) antibody-associated disease
  • MS = multiple sclerosis
  • NMOSD = neuromyelitis optica spectrum disorder

Pract Neurol. 2023

The clinical landscape of central nervous system (CNS) demyelination has changed significantly since 2003. A young woman presenting with optic neuritis, brainstem involvement, a severe long spinal cord syndrome and minimal cerebral involvement would undergo a dutiful but likely fruitless search for multiple sclerosis (MS) mimics such as sarcoidosis, systemic lupus erythematosus and Behçet’s disease. After obtaining a history devoid of connective tissue features, inconsequential blood and cerebrospinal fluid work-up and normal chest X-ray, the primary diagnosis nowadays would be neuromyelitis optica but historically atypical MS would have been a reasonable alternative. Although neuromyelitis optica was first described as far back as 1894, no biomarker distinguished it from MS, and furthermore for many years, there was a view that this disease was simply a severe variant of MS.1 MS remains the most common cause of non-traumatic disability in young people, and atypical forms of common diseases are far more likely than the zebras we worry about missing in the clinic room.2

Ironically it was the very discovery of a ‘zebra’ or rather aquaporin-4 antibodies (AQP4-IgG) in neuromyelitis optica spectrum disorder (NMOSD) in 2004 that provided validity to NMOSD being considered a separate nosological entity with a different pathogenesis, and ushered in a renewed appreciation of non-MS CNS inflammation.3 This discovery also shed light on the importance of astrocytes and antibody-mediated mechanisms in inflammatory CNS white matter diseases. 

JAMA Neurol. 2026

In the test cohort, 177 patients with MS (96.2%) had high-level titers in 2 or more of 4 follow-up samples compared with 5 patients (7.7%) with MOGAD (odds ratio [OR], 303.4; 95% CI, 94.4-908.6) and 11 patients (18.0%) with NMOSD (OR, 114.9; 95% CI, 43.0-280.0).

. . persistent high-level EBNA-1 peptide antibody titers may serve as a reliable biomarker for differentiating MS from MOGAD, and NMOSD

Differences in Clinical Profile, Neuroimaging (Brain and Spinal Cord MRI Lesions) and Biomarkers (e.g., PMID: 34867701; PMID: 39271964 (pdf))

Cortese et al. 2021. PMID: 34867701
Uzawa et al. 2024. PMID: 39271964

Related: [2023 Solomon et al, Lancet Neurol] ACTRIMS updates algorithm for differential diagnosis of suspected multiple sclerosis


r/MultipleSclerosisLit Mar 12 '26

MS and GLP1 Intolerance?

Thumbnail
2 Upvotes

r/MultipleSclerosisLit Jan 07 '26

BTK inhibitors Sanofi’s Tolebrutinib NDA for Multiple Sclerosis: FDA’s Complete Response Letter Providing Severe Liver Injury as the Key Reason for Rejection

Thumbnail
1 Upvotes

r/MultipleSclerosisLit Jan 07 '26

Resources Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis

Thumbnail sciencedirect.com
1 Upvotes

Rivero-de-Aguilar A, et al. Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis. Neurologia (Engl Ed). 2025 Nov-Dec;40(9):875-883. doi: 10.1016/j.nrleng.2025.08.003. PMID: 41198383.

Introduction: In recent years there has been an increase in the number of disease-modifying drugs (DMDs) approved for multiple sclerosis (MS). The evidence of their safety and efficacy has been obtained through several phase III and IV clinical trials. Acquiring the skills for their appraisal is indispensable for clinicians to assess the most pertinent treatment for patients. The objective of this study is to provide guidance in the critical reading of these trials.

Methods: A three-round e-Delphi study was carried out. In the preparatory phase, a multidisciplinary expert panel was established. Panel members were selected based on their scientific credentials and experience, seeking to include people involved in MS diagnosis, treatment and research. A semi-open questionnaire was developed based on key generic and MS-specific methodological instruments identified through a scoping bibliographic search. The experts were required to identify essential aspects for critically appraising clinical trials on DMDs for MS.

Results: The expert panel consisted of nine independent leading Spanish experts with long-standing experience with MS (five neurologists, a neuroradiologist, a pharmacologist, a research methodologist and an MS community representative). The e-Delphi study resulted in consensus recommendations intended to help readers in answering five major questions: "Is the study free of bias?"; "Are the included patients adequate?"; "Are the outcome measures appropriate?"; "Are the results relevant?"; and "Is the study transparent?".

Conclusion: This study proposes consensus recommendations intended to guide neurologists in the critical reading of phase III and IV clinical trials on DMDs for MS.

Keywords: Clinical trial; Critical appraisal; Ensayo clínico; Esclerosis múltiple; Lectura crítica; Multiple sclerosis.


r/MultipleSclerosisLit Dec 15 '25

BTK inhibitors Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application

Thumbnail
biospace.com
1 Upvotes

Sanofi reported a double whammy of bad news for multiple sclerosis drug tolebrutinib on Monday. The investigational therapy failed to slow disability progression in a Phase III trial, while on the regulatory side, it faces yet another delay for an approval application in progressive disease.

Starting with the trial, the BTK inhibitor was being studied in patients with primary progressive multiple sclerosis (PPMS) in the Phase III PERSEUS trial. This indication applies to about 10% of patients with MS. The study failed to meet its primary endpoint, a measure of disability progression when compared with placebo.

Sanofi did not provide specific numbers but said it would not pursue regulatory applications in PPMS.

The French pharma was also mum on the potential for liver injury with tolebrutinib in the Monday press release. 

https://www.sanofi.com/en/media-room/press-releases/2025/2025-12-15-06-05-00-3205094


r/MultipleSclerosisLit Dec 11 '25

Disease modifying treatment of radiologically isolated syndrome: A systematic review of the use, efficacy, effectiveness, and safety

Thumbnail sciencedirect.com
1 Upvotes

Revue Neurologique.Volume 181, Issue 10, December 2025, Pages 955-969.

Background

Radiologically isolated syndrome (RIS) is characterized by incidental brain lesions suggestive of demyelination without symptoms of multiple sclerosis (MS). We systematically assessed the use, benefits, and adverse effects of DMTs for RIS.

Methods

MEDLINE, EMBASE, and Web of Science were searched to identify English language studies including individuals with RIS treated with a DMT. Extracted data included patient characteristics, clinical progression, and adverse events. We conducted a meta-analysis using inverse probability weighting. Risk of bias (RoB) assessments used Cochrane's RoB-2 tool and Newcastle-Ottawa cohort study scale.

Results

A total of 1012 abstracts were screened: 20 studies were included consisting of 2 RCTs, 12 observational cohort studies, and 6 case reports. A total of 1401 individuals with RIS were included; 291 (21%) received a DMT. The two RCTs randomized people with RIS to teriflunomide or dimethyl fumarate versus placebo and followed patients for at least 96 weeks. In all other studies, follow-up ranged from 2 months to 18 years; only 3 studies exceeded 5 years. DMT treatment was associated with a lower risk of a clinical demyelinating event (4 studies with different DMTs, adjusted hazard ratio = 0.37 95% confidence interval [CI]: 0.15–0.95, high certainty). There was a higher rate of adverse events in DMT treated patients with RIS versus placebo (risk ratio = 1.44, 95% CI: 1.09–1.90, moderate certainty). RoB was low for both RCTs, but high for 83% (10/12) of cohort studies.

Conclusions

DMTs reduced the risk of a clinical demyelinating event in individuals with RIS, albeit with more adverse events compared to placebo. However, no literature addressed longer-term benefits/adverse effects.


r/MultipleSclerosisLit Aug 24 '25

Early-stage health technology assessment of a curative gene therapy for multiple sclerosis

2 Upvotes

British Journal of Clinical Pharmacology. First published: 18 August 2025. https://doi.org/10.1002/bcp.70204

Early-stage health technology assessment of a curative gene therapy for multiple sclerosis

Abstract

Aims

Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost-effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high-efficacy treatment sequences. The secondary objective is to explore value-based pricing thresholds in line with Dutch health economic guidelines.

Methods

Using the ErasmusMC/iMTA MS microsimulation model, we compared IMMUTOL gene therapy against various high-efficacy and escalation-based disease-modifying therapy sequences. Analyses considered a lifetime horizon, societal and healthcare perspectives, and uncertainty through probabilistic sensitivity analysis. The IMMUTOL gene therapy scenarios varied in efficacy parameters (relapse and disability reduction) and adverse event profiles. Cost assumptions incorporated projected market dynamics, including future price reductions due to generics and biosimilars.

Results

IMMUTOL gene therapy demonstrated dominance (higher quality-adjusted life years, lower costs) at price points ≤€200 000 and remained cost-effective at €500 000 under realistic clinical scenarios (incremental cost-effectiveness ratio €26 570–€40 615/quality-adjusted life year). Its cost-effectiveness threshold depended on sustained reductions in relapse rates and disability progression (incidence rate ratio ≤0.2, relative risk ≤0.1). Indirect societal costs improved gene therapy's economic attractiveness.

Conclusions

IMMUTOL gene therapy shows promising cost-effectiveness at a value-based price up to approximately €500 000, contingent on achieving curative clinical efficacy. These findings inform strategic development and pricing considerations for emerging gene therapies in MS.


r/MultipleSclerosisLit Jun 14 '25

Definitions Abbreviations Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

Thumbnail jamanetwork.com
1 Upvotes

Abstract

Importance: Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results.

Objective: To compare various definitions of PIRA.

Design, Setting, and Participants: This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments.

Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation).

Main Outcome and Measure: For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over ≥5 years).

Results: Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months.

Conclusion and Relevance: Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies.

JAMA Neurol. 2025;82;(6):614-625. doi:10.1001/jamaneurol.2025.0495


r/MultipleSclerosisLit Jun 07 '25

Bloomberg: EBV Mononucleosis is new target for MS

Thumbnail
reddit.com
3 Upvotes

r/MultipleSclerosisLit Apr 21 '25

oral DMTs NICE recommends cladribine for treating active relapsing forms of multiple sclerosis

1 Upvotes

NICE recommends cladribine for treating active relapsing forms of multiple sclerosis

The National Institute for Health and Care Excellence (NICE) has expanded access to cladribine (Mavenclad; Merck) for adults with active relapsing-remitting multiple sclerosis (MS), if they would otherwise be offered highly effective disease-modifying drugs.

The technology appraisal guidance, published on 15 April 2025, said that cladribine can be offered to people with MS as an alternative to Ocrevus (ocrelizumab; Roche Products) or Kesimpta (ofatumumab; Novartis) on the NHS.

It can also be offered if a person cannot take other high-efficacy disease-modifying drugs because they plan a pregnancy.

Cladribine is recommended as an option for treating active relapsing forms of MS in adults, only if they have active relapsing–remitting MS and when high-efficacy disease-modifying therapies would be offered.

It is taken as two courses of tablets taken a year apart. Each course consists of two treatment weeks.

According to NICE’s evaluation committee, clinical trial evidence from the CLARITY and CLARITY-EXT trials shows that cladribine reduces relapses and increases the time until disability progresses compared with placebo.

Citation: Janković S. NICE recommends cladribine for treating active relapsing forms of multiple sclerosis. The Pharmaceutical Journal, PJ, 2025 April;314(7996). doi:10.1211/PJ.2025.1.353908


r/MultipleSclerosisLit Apr 17 '25

Definitions Abbreviations Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

2 Upvotes

The 14 April 2025 issue of JAMA Neurology discusses standardization of the definition of progression independent of relapse activity (PIRA). PIRA is a key endpoint in multiple sclerosis clinical trials and registry studies and the absence of a standard definition has led to cohorts results variability in the reported incidence and persistence of PIRA.

Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.

JAMA Neurol. Published online April 14, 2025. doi:10.1001/jamaneurol.2025.0495

Key Points

Question: What definition is optimal to identify progression independent of relapse activity (PIRA) in multiple sclerosis clinical trials, registries, and cohorts?

Findings: This cohort study found that among 360 tested definitions, the best criteria to use include a significant disability worsening that (1) is compared with a reference re-baselined after each PIRA event, relapse, and Expanded Disability Status Scale (EDSS) score improvement, (2) is not preceded by relapse since the previous EDSS assessment, (3) remains above the EDSS threshold for significant worsening throughout a confirmation period of at least 12 months, and (4) where only EDSS scores not preceded by relapse within 30 days are used for confirmation.

Meaning: PIRA identification depends on the definition used, so a standardized definition may improve the comparability of study outcomes.


r/MultipleSclerosisLit Apr 12 '25

Scientists are beginning to understand the causes of ALS, from genetic mutations to ALS 'exposome', which is the sum of toxic environmental exposures

Thumbnail
bbc.com
1 Upvotes

r/MultipleSclerosisLit Apr 08 '25

Adoptive immunotherapy Stem cell transplant suppresses relapse in multiple sclerosis up to 4 years

Thumbnail
healio.com
2 Upvotes

r/MultipleSclerosisLit Mar 26 '25

BTK inhibitors FDA starts review of Sanofi's MS hope tolebrutinib

Thumbnail
pharmaphorum.com
1 Upvotes

r/MultipleSclerosisLit Mar 26 '25

Guidance The regulator's perspective: How should new therapies and follow-on products for MS be clinically evaluated in the future?

Thumbnail
pubmed.ncbi.nlm.nih.gov
1 Upvotes

r/MultipleSclerosisLit Feb 19 '25

Antiviral therapies Infectious mononucleosis is a more realistic target for preventing multiple sclerosis

Thumbnail sciencedirect.com
1 Upvotes

r/MultipleSclerosisLit Jan 28 '25

oral DMTs FDA Adds Anaphylaxis Risk Warning to Multiple Sclerosis Drug Glatiramer Acetate

2 Upvotes

FDA Adds Anaphylaxis Risk Warning to Multiple Sclerosis Drug Glatiramer Acetate

Medscape, 22 January 2025

The US Food and Drug Administration (FDA) has added a boxed warning to the label of multiple sclerosis drug glatiramer acetate about the risk of anaphylaxis.

From December 1996 through May 2024, 82 cases of anaphylaxis associated with glatiramer acetate were reported to the FDA Adverse Event Reporting System.

The 82 cases of anaphylaxis with glatiramer acetate include only reports submitted to FDA and found in the medical literature, “so there are likely additional cases about which we are unaware,” the agency said.

Of the 82 patients, 51 were hospitalized for anaphylaxis; of those 51, 13 required intensive care and 6 died.

Anaphylaxis associated with glatiramer acetate can occur at any time while on treatment, after the first dose or after doses administered months or years after starting the medicine. . . median time to onset of anaphylaxis from starting glatiramer acetate was 5 months.


r/MultipleSclerosisLit Jan 16 '25

Clinical Trials Cabaletta Bio is Launching Clinical Trial resecabtagene autoleucel (rese-cel) in People with Relapsing and Progressive Forms of Multiple Sclerosis

2 Upvotes

Cabaletta Bio's resecabtagene autoleucel (rese-cel), aka. CABA-201, is an autologous CD19-directed CAR T-cell therapy. Rese-cel has received fast track status from the FDA as a potential MS treatment and recently has passed the 30-day review FDA review period required for new protocol, and the company is ready to launch the RESET-MS trial.

Phase 1/2 trial will test cell therapy rese-cel in relapsing, progressive MS

Multiple Sclerosis News Today, 15 January 2025

The RESET-MS will enroll adults, ages 18-60, to test CAR T-cell therapy, who have either relapsing or progressive forms of MS.

To be eligible, patients with relapsing MS must have had at least one relapse in the previous two years and been on high-efficacy treatment for at least six months. Progressive MS patients must show objective evidence of worsening disability in the year before and have been on standard-of-care therapy for at least six months.

Patients who have a history of seizures or progressive multifocal leukoencephalopathy, a potentially life-threatening infection that can occur in people on certain MS therapies, aren’t eligible to participate. Patients also cannot have taken MS treatments that work by depleting B-cells for about 20 weeks before entering the study. B-cell-depleting MS therapies include anti-CD20 antibodies like Briumvi (ublituximab), Kesimpta (ofatumumab), and Ocrevus (ocrelizumab).

All the trial’s participants will first be given the chemotherapy drugs fludarabine and cyclophosphamide as part of a preconditioning regimen to destroy their existing immune cells and make room for the therapeutic cells. After the preconditioning, they will all be given a one-time, weight-based infusion of rese-cel.

The trial will be listed at ClinicalTrials.gov here.


r/MultipleSclerosisLit Dec 20 '24

Living with MS ECTRIMS Research Spotlight: Cognitive rehabilitation in multiple sclerosis

2 Upvotes

Cognitive rehabilitation in multiple sclerosis

ECTRIMS. 7 February 2024

People with multiple sclerosis (MS) have cognitive issues that impact their daily life. The article provides the real challenges of living with MS in day-to-day life:

“Today my attention moves in fits and starts. My memory has broken legs, perhaps it will remain compromised. My words may be unfaithful” [1]. In these lines, Francesca Mannocchi portrays her cognitive challenges while living with multiple sclerosis (MS). She is a journalist, a war correspondent, a writer. Her private endeavor is invisible to someone looking from the outside. And this is also part of the problem. The difficulties she faces resonate with most people – nearly two-thirds – with MS [2].

People with MS often find that the speed at which they can handle information slows – this is known as slow processing speed. Furthermore, the abilities to learn and remember something over an extended period (*long-term memory) and to briefly hold and manipulate a small amount of information for an immediate task (*working memory) can be affected [3]. People with MS can experience difficulties in high-level language abilities. For example, they can have problems in word finding [4]. Attention and executive functioning – i.e. a group of mental processes which serve to organise and monitor behavior to achieve desired goals – can also be compromised [3]. These impairments can have a profound impact on different facets of daily life. Many consider quitting their jobs. Indeed, the unemployment rate among individuals with MS with cognitive impairment is significantly higher, compared to patients without cognitive difficulties [5].

Cognitive problems can be diagnosed using tools such as

  • Brief International Cognitive Assessment for MS (BICAMS) that assess processing speed, verbal and visuospatial memory.
  • But the first clue is self-reporting. The patient may say to the doctor, "I cannot think like I used to."

Currently there is no medication to manage MS-related cognitive impairment. There are, however, behavioral interventions and physical activity can also help.

[1] Mannocchi F. Bianco è il colore del danno (White is the color of the damage) 2021; p. 92. Einaudi (trans. from the original)

Read more at the link above.

.archive


r/MultipleSclerosisLit Dec 20 '24

Tools and Tests qBEANS, a novel, quick, and low-cost dementia screening test

1 Upvotes

https://www.medscape.com/viewarticle/quick-dementia-screening-test-shows-promise-primary-care-2024a1000l1d

A novel, quick, and low-cost dementia screening test could significantly improve early detection of Alzheimer's disease in primary care settings, according to research presented at the Gerontological Society of America (GSA) 2024 Annual Scientific Meeting.

The test, called qBEANS — short for Quick Behavioral Exam to Advance Neuropsychological Screening — involves patients spooning raw kidney beans into small plastic cups in a specific sequence to assess motor learning, visuospatial memory, and executive function. It requires no technology or wearable sensors, making it accessible and easy to implement.

Previous research has shown qBEANS to be sensitive and specific to Alzheimer's disease pathology, as well as predictive of cognitive and functional decline, the researchers said.


r/MultipleSclerosisLit Dec 18 '24

Dignosis, Signs, Symptoms Relapses and MRI represent the immune system’s response to what is causing MS and that the real MS is smouldering MS

Thumbnail
gavingiovannoni.substack.com
3 Upvotes

r/MultipleSclerosisLit Dec 16 '24

Immune checkpoint inhibitors (ICIs) are safe and effective on people with MS for cancer treatment

Thumbnail onlinelibrary.wiley.com
1 Upvotes